In this issue

India Pharma Producing COVID19 Drugs For Masses

Known for its expertise in manufacturing and supplying quality generic drugs, Indian pharma sector is currently using the generic tool as a critical arsenal in the fight against COVID–19. At present, there are around 25 different drugs brands available in the Indian market to treat the COVID-19 patients, with many more in the pipeline

INDIAN PHARMA PRODUCING COVID - 19 DRUGS FOR MASSES

Known for its expertise in manufacturing and supplying quality generic drugs, Indian pharma sector is currently using the generic tool as a critical arsenal in the fight against COVID–19. At present, there are around 25 different drugs brands available in the Indian market to treat the COVID-19 patients, with many more in the pipeline.

10+ mins

Intellectual Property in doldrums

Governments around the globe have been waiving common Intellectual Property (IP) laws for the treatment of COVID-19, which has adversely impacted the world. This has become a matter of concern for pharmaceutical firms, who are fiercely protective of their IP. BioSpectrum Asia delves into IP during the coronavirus pandemic and its impact on pharma innovation.

5 mins

Time To Look For 2nd Gen Vaccines

Most pharmaceutical companies, across the world, are working at a breakneck speed to develop a vaccine for the novel coronavirus. Some companies are concerned that these vaccines may not be particularly effective in preventing COVID-19 infections in the long-term. This has evoked the need in them to develop improved, next-generation vaccines against the novel coronavirus. BioSpectrum discusses this next phase of vaccine development and if it’s too early to think about the second generation when we don’t even have the first ready yet.

6 mins

WHO on the centre stage

The COVID-19 pandemic, with Wuhan in China as its epicenter has wreaked havoc worldwide on a monumental scale. Nations of the world were caught unawares and so was the World Health Organization (WHO). It would seem that this globally active organization has not been able to lead the world in response to the pandemic. While some countries have been trying to fight and contain the spread on their own terms, many countries rely on the WHO for its experience in handling pandemics in the past. The United States of America, and particularly President Donald Trump has been a vocal critic of the WHO. We will take a look at how the global organization has handled previous epidemics and whether its criticism is warranted.

8 mins

LianBio – accelerating availability of paradigm-shifting medicines for Asian markets

New and dynamic companies are being formed to bridge the gap between global innovation and the China market and accelerate access to innovative new drugs from the US, Europe and elsewhere that address unmet patient needs. LianBio from China is one such company having mission to provide access to the best science-driven therapeutic discoveries to patients in China and major Asian markets.

5 mins

“Value of research conducted within academic institutions will be better appreciated in future”

Founded in 2009, Melbourne-based Affinity Biosciences, whose key focus is on discovering antibodies for cancer therapeutics, is now working on antibodies for COVID-19.

3 mins

“We are speeding up distribution of IFN-β-1a in Singapore for COVID-19 management”

One of the first companies to partner with Gilead to manufacture remdesivir for COVID-19 treatment, Singapore headquartered SRS Life Sciences is currently working on multiple projects to combat this pandemic. Suchet Rastogi, Chief Executive Officer, SRS Life Sciences spoke to BioSpectrum Asia and revealed the major steps being taken by the company currently. Edited excerpts;

2 mins

Simulating Technology Solutions To Fight Covid-19

Use of engineering simulation technology is common in the global healthcare industry. US Food and Drug Administration (FDA) & European regulatory agencies are encouraging the healthcare companies to use Computer Modeling & Simulation (CM&S) to aid the approval process for medical devices and achieve quality by design in pharmaceutical manufacturing.

3 mins

Invest in building agile supply chains

The current pandemic has significantly disrupted the global economy, not to mention business continuity for many companies.

3 mins

BIO Asia–Taiwan 2020: 1,400 delegates, 450 exhibitors take part in 5-day event

As the world is facing the unprecedented challenge of COVID-19, biomedical companies, emerging startups, MNC’s are being cooperative and rallying together to accelerate the development of therapeutics, diagnostics and vaccine to fight the global and regional healthcare crisis.

8 mins

Read all stories from BioSpectrum Asia

BioSpectrum Asia Magazine Description:

BioSpectrum Asia Magazine is a monthly magazine published by MM Activ Sci-Tech Communication in India. It is a leading biotechnology magazine in Asia, covering a wide range of topics related to the biotechnology industry, including:

* Biotechnology news and trends: BioSpectrum Asia covers the latest biotechnology news and trends from India and around the world.
* Biotechnology company profiles and interviews: The magazine profiles leading biotechnology companies in Asia and interviews their CEOs and other top executives.
* Biotechnology research and development: BioSpectrum Asia covers the latest biotechnology research and development from academic institutions and pharmaceutical companies.
* Biotechnology product reviews: The magazine reviews the latest biotechnology products and services.
* Biotechnology industry events: BioSpectrum Asia covers biotechnology industry events from around the world.

BioSpectrum Asia Magazine is a must-read for anyone who wants to stay informed about the latest advances in biotechnology and their potential to impact the world around us.